Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609

Influence of Helicobacter pylori infection on PD‐1/PD‐L1 blockade therapy needs more attention

Shi, Y., Zheng, H., Wang, M., & Ding, S. (2022) · Helicobacter · doi:10.1111/hel.12878 · Cited by 31

Research progress of tumor targeted drug delivery based on PD-1/PD-L1

Liu, D., Gao, S., Zhai, Y., Yang, X., & Zhai, G. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121527 · Cited by 30

Modulation of PDCD1 exon 3 splicing

Sun, J., Bai, J., Jiang, T., Gao, Y., & Hua, Y. (2019) · RNA Biology · doi:10.1080/15476286.2019.1659080 · Cited by 30

Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression

Gao, M. Q., Zhang, D., Jiang, C., Jin, Q., & Zhang, J. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115317 · Cited by 29

The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature

Tsiouprou, I., Zacharias, A., & Spyratos, D. G. (2019) · Canadian Respiratory Journal · doi:10.1155/2019/6860432 · Cited by 28

Flurbiprofen as a biphenyl scaffold for the design of small molecules binding to PD-L1 protein dimer

Bailly, C., & Vergoten, G. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114042 · Cited by 29

Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition

Zhi, J., Zhang, P., Zhang, W., Ruan, X., Tian, M., Guo, S., Zhang, W., Zheng, X., Zhao, L., & Gao, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa656 · Cited by 28

Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology

Tran, T. H., & Tran, T. T. P. (2022) · Royal Society Open Science · doi:10.1098/rsos.211991 · Cited by 27

Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical

Tang, C., Li, L., Mo, T., Na, J., Qian, Z., Fan, D., Sun, X., Yao, M., Pan, L., Huang, Y., et al. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02830-x · Cited by 28

Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding

Spodzieja, M., Kuncewicz, K., Sieradzan, A. K., Karczyńska, A. S., Iwaszkiewicz, J., Cesson, V., Wegrzyn, K. E., Zhukov, I., Maszota‐Zieleniak, M., Michielin, O. A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020636 · Cited by 27

Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis

Hu, X., Chen, S., Yin, H., Wang, Q., Duan, Y., Jiang, L., & Zhao, L. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.06.154 · Cited by 29

Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs

Giovannini, C., Fornari, F., Piscaglia, F., & Gramantieri, L. (2021) · Cells · doi:10.3390/cells10030521 · Cited by 27

Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma

Li, D., Shi, Z., Liu, X., Jin, S., Chen, P., Zhang, Y., Chen, G., Fan, X., Yang, J., & Lin, H. M. (2023) · Hepatology International · doi:10.1007/s12072-022-10460-2 · Cited by 27

Integration of active ingredients from traditional Chinese medicine with nano-delivery systems for tumor immunotherapy

Zheng, H., Chen, Y., Luo, W., Han, S., Sun, M., Min, L., Wu, C.-H., Gao, L., Xie, T., & Kong, N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03378-y · Cited by 27

High expression of PKM2 synergizes with PD-L1 in tumor cells and immune cells to predict worse survival in human lung adenocarcinoma

Long, L., Chen, M., Yuan, Y. J., Ming, A. L., Guo, W., Wu, K., & Chen, H. (2020) · Journal of Cancer · doi:10.7150/jca.42610 · Cited by 27

The safety and efficacy of neoadjuvant programmed death 1 inhibitor therapy with surgical resection in stage IIIA non-small cell lung cancer

Wang, J., Li, J., Cai, L., Chen, S., & Jiang, Y. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-670 · Cited by 26

The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis

Zeng, Y., Wei, X., Guo, Q., Chen, S., Sheng, D., Liu, Z., Gong, Z., & Zeng, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168244 · Cited by 27

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival

Chiarucci, C., Cannito, S., Daffinà, M. G., Amato, G., Giacobini, G., Cutaia, O., Lofiego, M. F., Fazio, C., Giannarelli, D., Danielli, R., et al. (2020) · Cancers · doi:10.3390/cancers12020361 · Cited by 26

Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies

Zhang, W., Chen, X., Chen, X., Li, J., Wang, H., Yan, X., Zha, H., Ma, X., Zhao, C., Su, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009034 · Cited by 26

Proposed mechanisms for the extracellular release of PD-L1 by the anticancer saponin platycodin D

Bailly, C., & Vergoten, G. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106675 · Cited by 25

Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy

Zhao, X., Wang, Y., Jiang, X., Mo, B., Wang, C., Tang, M., Rong, Y., Zhang, G., Hu, M., & Cai, H. (2023) · BMC Cancer · doi:10.1186/s12885-023-10564-4 · Cited by 24

Identification of the FDA‐Approved Drug Pyrvinium as a Small‐Molecule Inhibitor of the PD‐1/PD‐L1 Interaction

Fattakhova, E., Hofer, J., DiFlumeri, J., Cobb, M., Dando, T., Romisher, Z., Wellington, J., Oravic, M., Radnoff, M., & Patil, S. P. (2021) · ChemMedChem · doi:10.1002/cmdc.202100264 · Cited by 25

Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in Mice with Melanoma

Liang, L., Li, Y., Jiao, Y., Zhang, C., Shao, M., Jiang, H., Wu, Z., Chen, H., Guo, J., Jia, H., et al. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429259562230925055749 · Cited by 23

Molecular insight into T cell exhaustion in hepatocellular carcinoma

Zhu, Y., Tan, H., Wang, J., Zhuang, H., Zhao, H., & Lu, X. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107161 · Cited by 28

Design, synthesis, and structure-activity relationship of programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing a benzo[d]isothiazole scaffold

Chen, H., Wang, K., Yang, Y., Huang, X., Dai, X., & Feng, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113377 · Cited by 23

Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma

Nie, R., Yuan, S., Wang, Y., Chen, Y.-B., Cai, Y.-Y., Chen, S., Li, S.-M., Zhou, J., Chen, G., Luo, T., et al. (2019) · Aging · doi:10.18632/aging.102556 · Cited by 23

Prognostic and Therapeutic Implications of Immune Classification by CD8+ Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Sinonasal Squamous Cell Carcinoma

García-Marín, R., Reda, S., Riobello, C., Cabal, V. N., Suárez-Fernández, L., Vivanco, B., Álvarez-Marcos, C., López, F., Llorente, J., & Hermsen, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136926 · Cited by 16

NEIL3 contributes toward the carcinogenesis of liver cancer and regulates PI3K/Akt/mTOR signaling

Wang, W., Yin, Q., Guo, S., & Wang, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10487 · Cited by 22

Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer

Chen, P., Xu, J., Cui, Z., Wu, S., Xie, T., & Zhang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1071675 · Cited by 22

Cost-effectiveness analysis of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal squamous-cell carcinoma in China

Liu, S., Dou, L., & Li, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1055727 · Cited by 22

The Immunosuppressive Effect of TNFR2 Expression in the Colorectal Cancer Microenvironment

Salim, N. H. M., Mussa, A., Ahmed, N., Ahmad, S., Yean, C. Y., Hassan, R., Uskoković, V., Mohamud, R., & Jalil, N. A. C. (2023) · Biomedicines · doi:10.3390/biomedicines11010173 · Cited by 21

Prognostic markers in salivary gland cancer and their impact on survival

Szewczyk, M. P., Marszałek, A., Sygut, J., Golusiński, P., & Golusiński, W. (2019) · Head & Neck · doi:10.1002/hed.25857 · Cited by 22

PD‑L1 gene promoter methylation represents a potential diagnostic marker in advanced gastric cancer

Lv, D., Xing, C., Cao, L., Zhuo, Y., Wu, T., & Gao, N. (2019) · Oncology Letters · doi:10.3892/ol.2019.11221 · Cited by 22

Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies

Zhang, W., Lim, S.-M., Hwang, J., Ramalingam, S., Kim, M., & Jin, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02715-4 · Cited by 20

The expression and significance of efferocytosis and immune checkpoint related molecules in pancancer samples and the correlation of their expression with anticancer drug sensitivity

Cheng, L., Weng, B., Jia, C., Zhang, L., Hu, B., Deng, L., Mou, N., Sun, F., & Hu, J. Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.977025 · Cited by 20

Prognostic and Clinicopathological Significance of PD-L1 in Patients with Cholangiocarcinoma: A Meta-Analysis

Xie, Q., Wang, L., & Zheng, S. (2020) · Disease Markers · doi:10.1155/2020/1817931 · Cited by 20

Robotic-assisted colorectal surgery in colorectal cancer management: a narrative review of clinical efficacy and multidisciplinary integration

Chen, E., Chen, L., & Zhang, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1502014 · Cited by 21

Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis

Li, X., Zheng, Y., & Yue, F. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00763-5 · Cited by 19

Delivery of CRISPR/Cas9 Plasmid DNA by Hyperbranched Polymeric Nanoparticles Enables Efficient Gene Editing

Xiu, K., Saunders, L., Wen, L., Ruan, J., Dong, R., Song, J. W., Yang, D., Zhang, J., Xu, J., Chen, Y. E., et al. (2022) · Cells · doi:10.3390/cells12010156 · Cited by 19

PD-L1/BTLA Checkpoint Axis Exploited for Bacterial Immune Escape by Restraining CD8+ T Cell–Initiated Adaptive Immunity in Zebrafish

Hu, C., Huang, C., Wang, J., Hong, Y. M., Fan, D., Chen, Y., Lin, A., Xiang, L., & Shao, J.-Z. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300217 · Cited by 19

KERS‐Inspired Nanostructured Mineral Coatings Boost IFN‐γ mRNA Therapeutic Index for Antitumor Immunotherapy

Shao, Z., Chen, L., Zhang, Z., Wu, Y., Mou, H., Jin, X., Teng, W., Wang, F., Yang, Y., Zhou, H., et al. (2023) · Advanced Materials · doi:10.1002/adma.202304296 · Cited by 19

Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy

Xu, Y., Du, H., Guo, W., Liu, B., Yan, W., Zhang, C., Qin, L., Huang, J., Wang, H., Wu, S., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02362 · Cited by 19

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 19

Targeting lung cancer using advanced drug delivery systems

Paudel, K. R., Panth, N., Pangeni, R., Awasthi, R., Chawla, V., Mehta, M., Tambuwala, M. M., & Hansbro, P. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820658-4.00023-6 · Cited by 19

Disulfidptosis-related long non-coding RNA signature predicts the prognosis, tumor microenvironment, immunotherapy, and antitumor drug options in colon adenocarcinoma

Wang, K., Yu, J., Xu, Q., Peng, Y., Li, H., Lu, Y., & Ouyang, M. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02011-x · Cited by 18

Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials

Wang, Z., Wu, H., Xie, L., Lin, W., Liang, F., Li, J., Yang, Z., & Xu, R. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002114 · Cited by 17

Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through “ring fusion” strategy

Gao, Y., Wang, H., Shen, L., Xu, H., Deng, M., Cheng, M., & Wang, J. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105769 · Cited by 18

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas

Tsang, K. Y., Fantini, M. C., Mavroukakis, S. A., Zaki, A., Annunziata, C. M., & Arlen, P. M. (2022) · Cancers · doi:10.3390/cancers14133037 · Cited by 17

Berberine enhances the anti-hepatocellular carcinoma effect of NK92-MI cells through inhibiting IFN-gamma-mediated PD-L1 expression

Wang, K., Gu, C., Yu, G., Lin, J., Wang, Z., Lu, Q., Xu, Y., Zhao, D., Jiang, X., Mai, W., et al. (2022) · Liver Research · doi:10.1016/j.livres.2022.08.003 · Cited by 17

Review: PD‐L1 as an emerging target in the treatment and prevention of keratinocytic skin cancer

Vaishampayan, P., Curiel‐Lewandrowski, C. N., & Dickinson, S. E. (2022) · Molecular Carcinogenesis · doi:10.1002/mc.23464 · Cited by 18

Exploring the landscape of immunotherapy approaches in sarcomas

Pilavaki, P., Panagi, M., Arifi, S., Jones, R. L., Stylianopoulos, T., & Constantinidou, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1069963 · Cited by 17

Parathyroid hormone related protein (PTHrP)-mediated hypercalcemia in malignancy associated with anti-PD-1 immune checkpoint inhibitor treatment and related inflammatory reactions

Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105942 · Cited by 17

Phase I study of pucotenlimab (HX008), an anti-PD-1 antibody, for patients with advanced solid tumors

Liu, R., Li, W., Meng, Y., Gao, S., Zhang, J., & Hu, X. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211020528 · Cited by 16

Prognostic Value of GIMAP4 and Its Role in Promoting Immune Cell Infiltration into Tumor Microenvironment of Lung Adenocarcinoma

Chen, S., Tian, D., Petersen, L., Cao, S., Quinn, Z., Kan, J., Zheng, M., Mao, W., & Wan, Y. (2022) · BioMed Research International · doi:10.1155/2022/7440189 · Cited by 16

The Possible Role of PD-1 Protein in Ganoderma lucidum –Mediated Immunomodulation and Cancer Treatment

Wang, G., Wang, L., Zhou, J., & Xu, X. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419880275 · Cited by 16

Utilization of Immunotherapy as a Neoadjuvant Therapy for Liver Transplant Recipients with Hepatocellular Carcinoma

Abdelrahim, M., Esmail, A., Divatia, M. K., Xu, J., Kodali, S., Victor, D. W., Brombosz, E. W., Connor, A. A., Saharia, A., Elaileh, A., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113068 · Cited by 15

Camrelizumab (SHR-1210) leading to reactive capillary hemangioma in the gingiva: A case report

Yu, Q., & Wang, W. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i3.624 · Cited by 15

Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs

Zalba, S., Contreras-Sandoval, A. M., Martišová, E., Debets, R., Smerdou, C., & Garrido, M. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060595 · Cited by 15

A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma

Zhang, Y., Yin, X., Wang, Q., Song, X., Xia, W., Mao, Q., Chen, B., Liang, Y., Zhang, T., Xu, L., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08805-5 · Cited by 15

Upregulated ENC1 predicts unfavorable prognosis and correlates with immune infiltration in endometrial cancer

He, L., He, W., Luo, J., & Xu, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.919637 · Cited by 15

Specific T-cell immune responses against colony-forming cells including leukemic progenitor cells of AML patients were increased by immune checkpoint inhibition

Greiner, J., Götz, M., Hofmann, S., Schrezenmeier, H., Wiesneth, M., Bullinger, L., Döhner, H., & Schneider, V. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02490-2 · Cited by 16

Programmed cell death 1 (PDCD1) gene haplotypes and susceptibility of patients to basal cell carcinoma

Fathi, F., Zamani, B., Piroozmand, A., Mozafarpoor, S., Seyedhashemi, E., Arefnezhad, R., & Motedayyen, H. (2021) · Molecular Biology Reports · doi:10.1007/s11033-020-06115-w · Cited by 15

Oxymatrine Inhibits PD-L1 by Downregulating IFN-γ to Promote Ferroptosis and Enhance Anti-PD-L1 Efficacy in Liver Cancer

Nong, Y., Qin, H., Wei, L., Wei, X., Lv, J., Huang, X., & Wu, B. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s492582 · Cited by 14

Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis

Wang, Y., & He, H. (2022) · Immunotherapy · doi:10.2217/imt-2021-0238 · Cited by 14

Targeted immunotherapy to cancer stem cells: A novel strategy of anticancer immunotherapy

Yi, S., Wei, M.-Z., & Zhao, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104313 · Cited by 14

Prognostic role of non-neoplastic lymphocytes in lymph node aspirates from dogs with diffuse large B-cell lymphoma treated with chemo-immunotherapy

Martini, V., Aresu, L., Riondato, F., Marconato, L., Cozzi, M., Stefanello, D., & Comazzi, S. (2019) · Research in Veterinary Science · doi:10.1016/j.rvsc.2019.06.003 · Cited by 14

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient

Zhang, E., Zhang, Z.-Y., Li, J., & Huang, Z. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s284092 · Cited by 14

Prognostic value of tumor immune cell infiltration patterns in colon adenocarcinoma based on systematic bioinformatics analysis

Xu, H., Xu, Q., & Yin, L. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02048-x · Cited by 13

Improving ovarian cancer treatment decision using a novel risk predictive tool

Xu, Z., Song, J., Cao, L., Rong, Z., Zhang, W., He, J., Li, K., & Hou, Y. (2022) · Aging · doi:10.18632/aging.204023 · Cited by 14

Chemokine C‐C motif ligand 21 synergized with programmed death‐ligand 1 blockade restrains tumor growth

Chen, Q., Yin, H., Pu, N., Zhang, J., Zhao, G., Lou, W., & Wu, W. (2021) · Cancer Science · doi:10.1111/cas.15110 · Cited by 16

VSIG4 induces the immunosuppressive microenvironment by promoting the infiltration of M2 macrophage and Tregs in clear cell renal cell carcinoma

Zheng, X., Tong, T., Duan, L., Ma, Y., Lan, Y., Shao, Y., Liu, H., Chen, W., Yang, T., & Yang, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113105 · Cited by 14

PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy

Chen, L., Huang, S., Liu, Q., Kong, X., Su, Z., Zhu, M., Fang, Y., Zhang, L., Li, X., & Wang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.849468 · Cited by 13

CD8 + and FoxP3 + T‐Cell Cellular Density and Spatial Distribution After Programmed Death‐Ligand 1 Check Point Inhibition

Curry, J., Alnemri, A. E., Philips, R. H. W., Fiorella, M. A., Sussman, S. M., Stapp, R., Solomides, C., Harshyne, L. A., South, A. P., Luginbuhl, A., et al. (2022) · The Laryngoscope · doi:10.1002/lary.30389 · Cited by 13

Endocrine Adverse Events Related with Immune Checkpoint Inhibitors: An Update for Clinicians

Deligiorgi, M. V., Panayiotidis, M. I., & Trafalis, D. T. (2020) · Immunotherapy · doi:10.2217/imt-2019-0132 · Cited by 13

Tumor-regulated macrophage type 2 differentiation promotes immunosuppression in laryngeal squamous cell carcinoma

Zhang, P., Zhang, Y., Wang, L., & Lou, W. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118798 · Cited by 13

Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction

Fang, L., Tian, J., Zhang, K., Zhang, X., Liu, Y., Cheng, Z., Zhou, J., & Zhang, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116370 · Cited by 13

Molecular imaging of immune checkpoints in oncology: Current and future applications

Ge, S., Jia, T., Li, J., Zhang, B., Deng, S., & Sang, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215896 · Cited by 13

Immunotherapy in non‐small cell lung cancer: The past, the present, and the future

Lu, M., & Su, Y. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13012 · Cited by 13

Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer

Tahir, I. M., Rauf, A., Mehboob, H., Sadaf, S., Alam, M. S., Kalsoom, F., Bouyahya, A., Allam, A. E., Omari, N. E., Bakrim, S., et al. (2022) · Human Antibodies · doi:10.3233/hab-220001 · Cited by 12

Thiazole, a privileged scaffold in drug discovery

Alam, M. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18611-0.00027-9 · Cited by 12

Inhibitory receptors of plasmacytoid dendritic cells as possible targets for checkpoint blockade in cancer

Tiberio, L., Laffranchi, M., Zucchi, G., Salvi, V., Schioppa, T., Sozzani, S., Prete, A. D., & Bosisio, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1360291 · Cited by 13

Potential and unsolved problems of anti-PD-1/PD-L1 therapy combined with radiotherapy

Cao, Y., Li, W., Wang, Z., & Pang, H. (2020) · Tumori Journal · doi:10.1177/0300891620940382 · Cited by 12

Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series

Ligtenberg, K. G., Hu, J. K., Damsky, W., Olino, K. L., Kluger, H. M., Clune, J. E., Cowper, S. E., Panse, G., Leventhal, J. S., & Weiss, S. A. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.05.010 · Cited by 12

Disulfiram combined with chemoimmunotherapy potentiates pancreatic cancer treatment efficacy through the activation of cGAS-STING signaling pathway via suppressing PARP1 expression.

Huang, S., Xie, P., Huang, X., Chen, Z., Yang, J., Wang, J., Liu, C., Li, H., & Zhou, B. (2023) · PubMed Central · Cited by 11

Plant‐derived Durvalumab variants show efficient PD‐1/PD‐L1 blockade and therapeutically favourable FcR binding

Izadi, S., Gumpelmair, S., Coelho, P., Duarte, H. O., Gomes, J., Leitner, J. M., Kunnummel, V., Mach, L., Reis, C. A., Steinberger, P., et al. (2023) · Plant Biotechnology Journal · doi:10.1111/pbi.14260 · Cited by 10

A comprehensive analysis of the prognostic and immunological role of ANK3 in pan-cancer

Tan, Y., Meng, W., Jiang, Z., Li, N., Zhang, T., Zhang, J., Ma, L., & Guan, Y. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-2379 · Cited by 11

Activation of IL-2/IL-2R pathway by Hedyotis diffusa polysaccharide improves immunotherapy in colorectal cancer

Bai, L., Liu, X., Yuan, Z., Xu, G., Li, X., Wan, Z., Zhu, M., Liang, X., Li, P., Lan, Q., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.141013 · Cited by 11

The analysis of the pyroptosis-related genes and hub gene TP63 ceRNA axis in osteosarcoma

Han, J., Hu, Y., Ding, S., Liu, S., & Wang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.974916 · Cited by 12

Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Fang, R., Wang, S., Liu, Y., & Xu, J. (2023) · Advances in Therapy · doi:10.1007/s12325-022-02402-z · Cited by 11

Stigmasterol Exerts an Anti-Melanoma Property through Down-Regulation of Reactive Oxygen Species and Programmed Cell Death Ligand 1 in Melanoma Cells

Han, N.-R., Park, H.-J., Ko, S.-G., & Moon, P. (2024) · Antioxidants · doi:10.3390/antiox13030380 · Cited by 11

Insights into small molecule inhibitor bindings to PD-L1 with residue-specific binding free energy calculation

Xia, W., He, L., Bao, J., Qi, Y., & Zhang, J. Z. H. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1971558 · Cited by 10

Tumor-endogenous PD-1 promotes cell proliferation and predicts poor survival in non-small cell lung cancer

Gan, F., Zhang, C., Xia, L. P., & Deng, S. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-1644 · Cited by 10

Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer

Zhu, Y., Zuo, D., Wang, X., Lan, S., He, H., Chen, L., Chen, X., & Feng, M. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05279-9 · Cited by 10

Current strategies of virotherapy in clinical trials for cancer treatment

Lin, W., Zhao, Y., & Zhong, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26947 · Cited by 10

Pd-l1 expression in medullary thyroid carcinoma and its association with clinicopathological findings

Kemal, Y., Çalışkan, S., Gün, S., & Kefeli, M. (2021) · Turkish Journal of Pathology · doi:10.5146/tjpath.2021.01558 · Cited by 10

Limiting tumor seeding as a therapeutic approach for metastatic disease

Worrede, A., Meucci, O., & Fatatis, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.007 · Cited by 11

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review

Shen, T. H., Zheng, S., Geng, L., Liu, Z., Xu, J., Lin, B., Qian, J., & Zheng, S. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820979703 · Cited by 10

Inhibition of UV-Induced Stress Signaling and Inflammatory Responses in SKH-1 Mouse Skin by Topical Small-Molecule PD-L1 Blockade

Dickinson, S. E., Vaishampayan, P., Jandová, J., Ai, Y., Kirschnerova, V., Zhang, T., Calvert, V. S., Petricoin, E. F., Chow, H. ‐. S., Hu, C., et al. (2024) · JID Innovations · doi:10.1016/j.xjidi.2023.100255 · Cited by 9

DNA damage response-related signatures characterize the immune landscape and predict the prognosis of HCC via integrating single-cell and bulk RNA-sequencing

Li, H., Shi, Y., Li, Y., Wu, S., Yang, R., Liu, Q., & Sun, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112475 · Cited by 9

A patent review of small molecule CDK4/6 inhibitors in the treatment of cancer: 2020–present

Huang, X., Xu, S., Duan, L., Xu, S., & Zhu, W. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2379926 · Cited by 9

Cancer Immunotherapy Beyond PD1/PD-L1

Dr. D. Rama Bramha Reddy, K. M. (2026) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.21927064

Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Gong, J., Chehrazi‐Raffle, A., Reddi, S., & Salgia, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0316-z · Cited by 1,307

Spectrum and Clinical Activity of PD-1/PD-L1 Inhibitors: Regulatory Approval and Under Development

Oliveira, L. J. D. C., Gongora, A. B. L., & Jardim, D. L. F. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00928-5 · Cited by 19

Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics

Abaza, A., Sid Idris, F., Anis Shaikh, H., Vahora, I., Moparthi, K. P., Al Rushaidi, M. T., Muddam, M. R., Obajeun, O. A., Jaramillo, A. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.44582 · Cited by 59

Overview of PD-1 and PD-L1 Inhibitors

Andreatos, N., Bhatia, S., & Grivas, P. D. (2019) · Springer Publishing Company eBooks · doi:10.1891/9780826172150.0002